127 related articles for article (PubMed ID: 37648148)
1. Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells.
Zhuo FF; Li L; Liu TT; Liang XM; Yang Z; Zheng YZ; Luo QW; Lu JH; Liu D; Zeng KW; Tu PF
Cancer Lett; 2023 Oct; 573():216364. PubMed ID: 37648148
[TBL] [Abstract][Full Text] [Related]
2. SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.
Wang B; Ye Y; Yang X; Liu B; Wang Z; Chen S; Jiang K; Zhang W; Jiang H; Mustonen H; Puolakkainen P; Wang S; Luo J; Shen Z
EMBO Rep; 2020 Apr; 21(4):e48183. PubMed ID: 32141187
[TBL] [Abstract][Full Text] [Related]
3. Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating β-oxygenation pathway in colorectal cancer.
Koseki J; Colvin H; Fukusumi T; Nishida N; Konno M; Kawamoto K; Tsunekuni K; Matsui H; Doki Y; Mori M; Ishii H
Int J Oncol; 2015 Mar; 46(3):1181-91. PubMed ID: 25586680
[TBL] [Abstract][Full Text] [Related]
4. TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity.
Yang H; Zhao X; Liu J; Jin M; Liu X; Yan J; Yao X; Mao X; Li N; Liang B; Xie W; Zhang K; Zhao J; Liu L; Huang G
Oncogene; 2023 Jan; 42(1):35-48. PubMed ID: 36352097
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin activation targets IDH-mutant tumors.
Miller JJ; Fink A; Banagis JA; Nagashima H; Subramanian M; Lee CK; Melamed L; Tummala SS; Tateishi K; Wakimoto H; Cahill DP
Neuro Oncol; 2021 Jan; 23(1):53-62. PubMed ID: 32710757
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular anti-metastasis mechanisms of lycorine in colorectal cancer by RNA-seq analysis.
Gao L; Feng Y; Ge C; Xu X; Wang S; Li X; Zhang K; Wang C; Dai F; Xie S
Phytomedicine; 2021 May; 85():153530. PubMed ID: 33761445
[TBL] [Abstract][Full Text] [Related]
7. Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts
Zhang P; Yuan X; Yu T; Huang H; Yang C; Zhang L; Yang S; Luo X; Luo J
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649853
[TBL] [Abstract][Full Text] [Related]
8. Correlation of IDH1 and B7H3 expression with prognosis of CRC patients.
Wu J; Wang F; Liu X; Zhang T; Liu F; Ge X; Mao Y; Hua D
Eur J Surg Oncol; 2018 Aug; 44(8):1254-1260. PubMed ID: 29871819
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
Gonthier K; Poluri RTK; Weidmann C; Tadros M; Audet-Walsh É
Mol Cancer Res; 2019 Aug; 17(8):1699-1709. PubMed ID: 31068457
[TBL] [Abstract][Full Text] [Related]
11. Computational study on novel natural compound inhibitor targeting IDH1_R132H.
Zhou B; Yang F; Qin L; Kuai J; Yang L; Zhang L; Sun P; Li G; Wang X
Aging (Albany NY); 2022 Jul; 14(13):5478-5492. PubMed ID: 35802554
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets.
Wu Z; Xiao C; Long J; Huang W; You F; Li X
Cell Commun Signal; 2024 Feb; 22(1):91. PubMed ID: 38302953
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of nuclear deacetylase Sirtuin-1 induces mitochondrial acetylation and calcium overload leading to cell death.
Sun Y; Yang YM; Hu YY; Ouyang L; Sun ZH; Yin XF; Li N; He QY; Wang Y
Redox Biol; 2022 Jul; 53():102334. PubMed ID: 35636016
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA
Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
16. Absence of IDH mutation in colorectal cancers with microsatellite instability.
Tougeron D; Guilloteau K; Karayan-Tapon L
Dig Liver Dis; 2016 Jun; 48(6):681-3. PubMed ID: 26987944
[TBL] [Abstract][Full Text] [Related]
17. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
[TBL] [Abstract][Full Text] [Related]
19. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas.
Patrick S; Gowda P; Lathoria K; Suri V; Sen E
J Cell Sci; 2021 Nov; 134(22):. PubMed ID: 34651186
[TBL] [Abstract][Full Text] [Related]
20. Mutation of IDH1 aggravates the fatty acid‑induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain.
Li S; Sun C; Gu Y; Gao X; Zhao Y; Yuan Y; Zhang F; Hu P; Liang W; Cao K; Zhang J; Wang Z; Ye J
Mol Med Rep; 2019 Apr; 19(4):2509-2518. PubMed ID: 30720071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
